Stay updated on Reslizumab in EGPA: Clinical Trial
Sign up to get notified when there's something new on the Reslizumab in EGPA: Clinical Trial page.

Latest updates to the Reslizumab in EGPA: Clinical Trial page
- Check6 days agoChange DetectedAdded a dedicated 'Locations' section featuring the Colorado site. Removed the old 'Colorado Locations' entry and the 'HHS Vulnerability Disclosure' link from the footer.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe PubMed publications note has been updated to say that publications are automatically filled from PubMed and may not be about the study. The revision label has been updated to v3.3.2.SummaryDifference0.1%

- Check35 days agoChange DetectedThe funding-status notice banner was removed from the page, eliminating the warning about potential delays in updates due to government funding. The study details and other content remain unchanged.SummaryDifference0.4%

- Check57 days agoChange DetectedNo significant changes observed between the old and new Study Details pages. Core study information and navigation remain the same.SummaryDifference0.5%

- Check78 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference4%

- Check85 days agoChange Detected- Version updated from v3.0.2 to v3.1.0. - New contact details added: multiple phone numbers and an email.SummaryDifference0.1%

Stay in the know with updates to Reslizumab in EGPA: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reslizumab in EGPA: Clinical Trial page.